Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant giredestrant versus physician's choice endocrine monotherapy in ER-positive/HER2-negative early breast cancer
jRCT2031210363Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of giredestrant in breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Invasive disease-free survival excluding second primary non-breast cancers. Started Dec 2021; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031210363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210363.